Ovarian cancer emerging subtypes: Role of oxidative stress and fibrosis in tumour development and response to treatment

International Journal of Biochemistry and Cell Biology

Volumn 45, Issue 6, 2013, Pages 1092-1098

  Batista, L ^a,b   Gruosso, T ^a,b   Mechta Grigoriou, F ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

Author keywords

microRNA miR 200 NRF2 Response to chemotherapy Signatures ROS

Indexed keywords

MICRORNA; TRANSCRIPTOME;

CANCER CHEMOTHERAPY; FEMALE; HUMAN; OVARY CANCER; OXIDATIVE STRESS; PATIENT SELECTION; REVIEW; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84875936619     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2013.03.001     Document Type: Short Survey

References (38)

1. A. Bendoraite, E.C. Knouf, K.S. Garg, R.K. Parkin, E.M. Kroh, and K.C. O'Briant Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition Gynecologic Oncology 116 2010 117 125
2. S. Bentink, B. Haibe-Kains, T. Risch, J-B. Fan, M.S. Hirsch, and K. Holton Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer PLoS ONE 7 2012 e30269
3. A.H. Bild, G. Yao, J.T. Chang, Q. Wang, A. Potti, and D. Chasse Oncogenic pathway signatures in human cancers as a guide to targeted therapies Nature 439 2005 353 357
4. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer New England Journal of Medicine 365 2011 2473 2483
5. D.W. Chan, V.W.S. Liu, G.S.W. Tsao, K-M. Yao, T. Furukawa, and K.K.L. Chan Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells Carcinogenesis 29 2008 1742 1750
6. C.J. Creighton, A. Hernandez-Herrera, A. Jacobsen, D.A. Levine, P. Mankoo, and N. Schultz Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma PLoS ONE 7 2012 e34546
7. R. Eitan, M. Kushnir, G. Lithwick-Yanai, M.B. David, M. Hoshen, and M. Glezerman Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients Gynecologic Oncology 114 2009 253 259
8. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, and M. Mergui-Roelvink Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers New England Journal of Medicine 361 2009 123 134
9. D. Gerald, E. Berra, Y.M. Frapart, D.A. Chan, A.J. Giaccia, and D. Mansuy JunD reduces tumor angiogenesis by protecting cells from oxidative stress Cell 118 2004 781 794
10. J. Helleman, M. Smid, M.P.H.M. Jansen, M.E.L. Van der Burg, and E.M.J.J. Berns Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture Gynecologic Oncology 117 2010 170 176
11. X. Hu, D.M. Macdonald, P.C. Huettner, Z. Feng, I.M. El Naqa, and J.K. Schwarz A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer Gynecologic Oncology 114 2009 457 464
12. M.V. Iorio, R. Visone, G.D. Leva, V. Donati, F. Petrocca, and P. Casalini MicroRNA signatures in human ovarian cancer Cancer Research 67 2007 8699 8707
13. C.W. Kan, M.A. Hahn, G.B. Gard, J. Maidens, J.Y. Huh, and D.J. Marsh Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer BMC Cancer 12 2012 627
14. P.A. Konstantinopoulos, D. Spentzos, E. Fountzilas, N. Francoeur, S. Sanisetty, and A.P. Grammatikos Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer Cancer Research 71 2011 5081 5089
15. P.A. Konstantinopoulos, D. Spentzos, B.Y. Karlan, T. Taniguchi, E. Fountzilas, and N. Francoeur Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer Journal of Clinical Oncology 28 2010 3555 3561
16. J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, and G. Rustin Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer New England Journal of Medicine 366 2012 1382 1392
17. S. Leskelä, L.J. Leandro-García, M. Mendiola, J. Barriuso, L. Inglada-Pérez, and I. Muñoz The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients Endocrine-Related Cancer 18 2011 85 95
18. A. Magenta, C. Cencioni, P. Fasanaro, G. Zaccagnini, S. Greco, and G. Sarra-Ferraris miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition Cell Death & Differentiation 18 2011 1628 1639
19. S. Marchini, D. Cavalieri, R. Fruscio, E. Calura, D. Garavaglia, and I.F. Nerini Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections The Lancet Oncology 12 2011 273 285
20. B. Mateescu, Luciana Batista, M. Cardon, T. Gruosso, Y. de Feraudy, and O. Mariani miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response Nature Medicine 17 2011 1627 1635
21. D. Mezzanzanica, M. Bagnoli, L. De Cecco, B. Valeri, and S. Canevari Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications The International Journal of Biochemistry & Cell Biology 42 2010 1262 1272
22. E.J. Nam, H. Yoon, S.W. Kim, H. Kim, Y.T. Kim, and J.H. Kim MicroRNA expression profiles in serous ovarian carcinoma Clinical Cancer Research 14 2008 2690 2695
23. G. Pani, T. Galeotti, and P. Chiarugi Metastasis: cancer cell's escape from oxidative stress Cancer and Metastasis Reviews 29 2010 351 378
24. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer New England Journal of Medicine 365 2011 2484 2496
25. L. Raj, T. Ide, A.U. Gurkar, M. Foley, M. Schenone, and X. Li Selective killing of cancer cells by a small molecule targeting the stress response to ROS Nature 475 2011 231 234
26. R. Sabatier, P. Finetti, J. Bonensea, J. Jacquemier, J. Adelaide, and E. Lambaudie A seven-gene prognostic model for platinum-treated ovarian carcinomas British Journal of Cancer 105 2011 304 311
27. S. Sarojini, A. Tamir, H. Lim, S. Li, S. Zhang, and A. Goy Early detection biomarkers for ovarian cancer Journal of Oncology 2012 2012 1 15
28. K.K. Shih, L-X. Qin, E.J. Tanner, Q. Zhou, M. Bisogna, and F. Dao A microRNA survival signature (MiSS) for advanced ovarian cancer Gynecologic Oncology 121 2011 444 450
29. M.B. Sporn, and K.T. Liby NRF2 and cancer: the good, the bad and the importance of context Nature Reviews Cancer 12 2012 564 571
30. D.D. Taylor, and C. Gercel-Taylor MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer Gynecologic Oncology 110 2008 13 21
31. TCGA Network TCGAR Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
32. R.W. Tothill, A.V. Tinker, J. George, R. Brown, S.B. Fox, and S. Lade Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome Clinical Cancer Research 14 2008 5198 5208
33. A. Toullec, D. Gerald, G. Despouy, B. Bourachot, M. Cardon, and S. Lefort Oxidative stress promotes myofibroblast differentiation and tumour spreading EMBO Molecular Medicine 2 2010 211 230
34. M.T.M. van Jaarsveld, J. Helleman, E.M.J.J. Berns, and E.A.C. Wiemer MicroRNAs in ovarian cancer biology and therapy resistance The International Journal of Biochemistry & Cell Biology 42 2010 1282 1290
35. F. Weinberg, and N.S. Chandel Reactive oxygen species-dependent signaling regulates cancer Cellular and Molecular Life Sciences 66 2009 3663 3673
36. S.K. Wyman, R.K. Parkin, P.S. Mitchell, B.R. Fritz, K. O'Briant, and A.K. Godwin Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries PLoS ONE 4 2009 e5311
37. W.Z. Wysham, P. Mhawech-Fauceglia, H. Li, L. Hays, S. Syriac, and T. Skrepnik BRCAness profile of sporadic ovarian cancer predicts disease recurrence PLoS ONE 7 2012 e30042
38. H. Yang, W. Kong, L. He, J-J. Zhao, J.D. O'Donnell, and J. Wang MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN Cancer Research 68 2008 425 433